Santosh University Journal of Health Sciences

---

Analyzing Efficacy of AMLEXANOX in Treatment of Recurrent Oral Apthosis

Full Text PDF Share on Facebook Share on Twitter

---

Original Article

Author Details : Sanjeev Laller, Mamta Malik, Ravinder S Saini, Divya Vardaini, Meenakshi Sharma, Anjali Ahlawat

Volume : 2, Issue : 1, Year : 2016

Article Page : 18-20

Suggest article by email

---

Abstract

Background: Recurrent aphthous stomatitis (RAS) is a multifactorial disorder which is common in 20% of society characterized by recurrent oral ulcer in person who does not have other sign of sickness. The aim this study was to evaluate and compare efficacy of anti-inflammatory agent amlexanox and topical anesthetic agent in reducing ulcer size and pain.
Materials and Methods: The effectiveness of healing ulcer measured using two parameters, which are the ulcer size and pain score. Thirty patients (n = 30) with minor recurrent aphthous stomatitis were selected for the study, with no known medical illness. Subjects were divided into two groups. Study group (Group-A) received Amlexanox (5%) and the other control group (Group-B) received topical anesthetic agent. The subjects were required to apply the medication 4 times per day. Ulcer size and pain were been measured on treatment days 1 and 4. Data were analyzed using t test for independent sample.
Results: Significant reduction in ulcer size and pain was noticed in study group (Group-A) as compared to control group (Group-B).
Conclusion: Amlexanox can reduce the ulcer size and pain associated with the aphthous ulcers with no side effects of the drug.

Keywords: Recurrent aphthous stomatitis (RAS), Oral Apthosis, Amlexanox, Visual Analogue Scale (VAS)

How to cite : Laller S, Malik M, Saini R S, Vardaini D, Sharma M, Ahlawat A, Analyzing Efficacy of AMLEXANOX in Treatment of Recurrent Oral Apthosis. Santosh Univ J Health Sci 2016;2(1):18-20

Copyright © 2016 by author(s) and Santosh Univ J Health Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)